For instance, while ADA1-engineered CAR T cells may thrive in adenosine-rich cancers such as hepatocellular carcinoma, their efficacy in tumors with alternative dominant suppressive pathways remains uncertain. This evidence concerns the gene ADA and hepatocellular carcinoma.